Platelet Membrane‐Fused Circulating Extracellular Vesicles Protect the Heart from Ischemia/Reperfusion Injury
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Jizong Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), School of…. Hauptthemen laut MEDLINE: Reperfusion Injury, Extracellular Vesicles, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Myocardial ischemia/reperfusion injury (I/RI) may potentiate cardiac remodeling and heart failure, while effective therapies for I/RI remain lacking. Circulating human plasma‐derived extracellular vesicles (hEV) have great potential to protect against I/RI. However, the effective delivery of hEV in vivo remains a limiting factor for clinical application. The present study constructs a biomimetic delivery system of platelet membrane‐fused hEV (P‐hEV), utilizing the natural affinity of platelets for hEV delivery to the injured vascular and myocardial sites. The results show that platelet membrane and hEV membrane fusion can be achieved through repeated extrusion. Compared to non‐modified hEV, P‐hEV uptake is greatly enhanced in human umbilical vein endothelial cells (HUVECs) stressed by oxygen‐glucose deprivation/reperfusion (OGD/R). Functionally, P‐hEV inhibits HUVEC and neonatal rat cardiomyocyte (NRCM) apoptosis and promotes HUVECs migration and tube formation under OGD/R stress in vitro. Intravenous delivery of P‐hEV more effectively targets and accumulates at injury sites in the heart. Furthermore, P‐hEV significantly enhances protection against acute I/RI and attenuates cardiac remodeling at three weeks post‐I/RI. In conclusion, the platelet membrane‐fused hEV delivery system enhances the target delivery of EV to protect against myocardial I/RI, presenting a novel drug delivery system for ischemic heart diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), School of Medicine, Shanghai University, Nantong, 226011, China.
- Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, 200444, China.
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
ORCID-Profile: Yihua Bei
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Jiang, J., Ni, L., Zhang, X., Wang, H., Liu, L., Wei, M., Li, G., & Bei, Y. (2023). Platelet Membrane‐Fused Circulating Extracellular Vesicles Protect the Heart from Ischemia/Reperfusion Injury. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300052
Vancouver
Jiang J, Ni L, Zhang X, Wang H, Liu L, Wei M, et al. Platelet Membrane‐Fused Circulating Extracellular Vesicles Protect the Heart from Ischemia/Reperfusion Injury. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300052
BibTeX
@article{Jiang2023,
author = {Jiang, Jizong and Ni, Lingyan and Zhang, Xinxin and Wang, Hongyun and Liu, Li and Wei, Meng and Li, Guoping and Bei, Yihua},
title = {Platelet Membrane‐Fused Circulating Extracellular Vesicles Protect the Heart from Ischemia/Reperfusion Injury},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300052}
}
EUVIMED